Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
Sponsor: Dasher Neuroscience Inc.
Summary
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Official title: A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy
Key Details
Gender
All
Age Range
30 Years - Any
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2025-03-03
Completion Date
2026-12-31
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
YA-101
Drug: YA-101 • YA-101 taken BID
Placebo
Placebo taken BID
Locations (9)
UCLA Health
Los Angeles, California, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Columbia University Irving medical center
New York, New York, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
Juntendo University Hospital
Tokyo, Japan
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital Cancer Center
Taipei, Taiwan